Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 697-698

  Lunghi, Monia ^a   Riccomagno, Paola ^a   De Paoli, Lorenzo ^a   Vendramin, Chiara ^a   Conconi, Annarita ^a   Gaidano, Gianluca ^a   Rossi, Davide ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; IMMUNOGLOBULIN; MITOXANTRONE; PREDNISONE; SERUM ALBUMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALBUMIN BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VIRUS REACTIVATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MONITORING, PHYSIOLOGIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; VIRUS ACTIVATION;

EID: 70349504372     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21494     Document Type: Letter

References (7)

1. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Mcrobiol Rev 2003;16:647-657. (Pubitemid 37296553)
2. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003;102:1232-1240. (Pubitemid 36988027)
3. Amadori S, Suciu S, Jehn U, et al.;EORTC/GIMEMA Leukemia Group. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005;106:27-34.
4. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
5. Cimino G, Elia L, Mancini M, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: Absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003;102:2014-2020. (Pubitemid 37122374)
6. Borthakur G, Lin E, Faderl S, et al. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 2007;110:2478-2483. (Pubitemid 350174933)
7. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125-130. (Pubitemid 44596594)